Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Therapy With Targeted Therapy Followed by Surgery for Stage IIIB and IV NSCLC
NCT05085054Phase 2Unknown
- Start
- Jun 2022
- Primary completion
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of osimertinib in non-small cell lung cancer (NSCLC). Primary endpoint: Progression-Free Survival at 3 years. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05085054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05085054.